chronic-pain
(2)
Michael Onuscheck
Michael Onuscheck is CEO and Chairman of Presidio Medical, a San Mateo clinical-stage neuromodulation company developing an ultra-low-frequency waveform platform aimed at chronic pain. He joined in September 2021 after two years on the board, returning to neuromodulation after leading Alcon's global businesses and, earlier, Boston Scientific's Neuromodulation division.
Mike Rosenbluth
Mike Rosenbluth is the Founder and CEO of Swing Therapeutics, the San Francisco-based company behind Stanza - the first FDA-authorized prescription digital therapeutic for fibromyalgia symptoms. A Stanford-trained mechanical engineer with a UC Berkeley PhD in Bioengineering, Rosenbluth spent years at McKinsey, a VC firm (Versant Ventures), and cancer diagnostics company Veracyte before founding Swing in 2019. His company's landmark PROSPER-FM Phase 3 trial results were published in The Lancet in 2024, and Swing has raised over $30 million to bring evidence-based, non-drug behavioral therapy to the estimated 4 million Americans with fibromyalgia.